Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Sells $41,352.08 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 13,426 shares of the business’s stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total value of $41,352.08. Following the completion of the sale, the chief financial officer owned 1,195,349 shares of the company’s stock, valued at $3,681,674.92. This trade represents a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded up $0.19 on Thursday, reaching $3.72. The stock had a trading volume of 20,264,585 shares, compared to its average volume of 21,761,594. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60. The company has a market cap of $1.93 billion, a P/E ratio of -2.07 and a beta of 0.95. The firm has a fifty day moving average of $4.28 and a two-hundred day moving average of $4.79. Recursion Pharmaceuticals, Inc. has a 1-year low of $2.98 and a 1-year high of $10.87.

Wall Street Analyst Weigh In

Several brokerages have weighed in on RXRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.40.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RXRX. TD Waterhouse Canada Inc. raised its holdings in Recursion Pharmaceuticals by 64.1% in the 2nd quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after buying an additional 2,200 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $31,000. Sequoia Financial Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd boosted its holdings in Recursion Pharmaceuticals by 97.2% in the second quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after acquiring an additional 4,446 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in Recursion Pharmaceuticals by 85.6% in the third quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.